Send to:

Choose Destination
See comment in PubMed Commons below
Curr Psychiatry Rep. 2008 Dec;10(6):510-9.

A review of the preclinical and clinical evidence for protein kinase C as a target for drug development for bipolar disorder.

Author information

  • 1Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, and Department of Health and Human Services, 10 Center Drive, CRC, Unit 7 Southeast, Room 7-3445, Bethesda, MD 20892, USA.


In this article, we review preclinical studies investigating the role of protein kinase C (PKC) as it pertains to mania and effective antimanic agents. We then discuss clinical studies conducted with tamoxifen, a relatively selective PKC inhibitor, in acute bipolar mania. We conclude that PKC is an important target-arguably the first mechanistically distinct drug target for bipolar disorder. PKC holds considerable promise as a novel target for developing a new line of treatments for bipolar disorder.

[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk